ZA200708086B - Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands - Google Patents

Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands

Info

Publication number
ZA200708086B
ZA200708086B ZA200708086A ZA200708086A ZA200708086B ZA 200708086 B ZA200708086 B ZA 200708086B ZA 200708086 A ZA200708086 A ZA 200708086A ZA 200708086 A ZA200708086 A ZA 200708086A ZA 200708086 B ZA200708086 B ZA 200708086B
Authority
ZA
South Africa
Prior art keywords
dementia
parkinson
disease
treatment
sleep apnea
Prior art date
Application number
ZA200708086A
Other languages
English (en)
Inventor
Schwartz Jean-Charles
Lecomte Jeanne-Marie
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35169680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200708086(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of ZA200708086B publication Critical patent/ZA200708086B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
ZA200708086A 2005-04-01 2007-09-20 Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands ZA200708086B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05290727A EP1707203A1 (en) 2005-04-01 2005-04-01 Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands

Publications (1)

Publication Number Publication Date
ZA200708086B true ZA200708086B (en) 2008-10-29

Family

ID=35169680

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708086A ZA200708086B (en) 2005-04-01 2007-09-20 Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands

Country Status (27)

Country Link
US (1) US8486947B2 (xx)
EP (2) EP1707203A1 (xx)
JP (3) JP5546761B2 (xx)
KR (1) KR101308527B1 (xx)
CN (1) CN101171009B (xx)
AU (1) AU2006228413C1 (xx)
BR (1) BRPI0612216B1 (xx)
CA (1) CA2603656C (xx)
CY (1) CY1114636T1 (xx)
DK (1) DK1863487T4 (xx)
EA (1) EA016007B1 (xx)
ES (1) ES2426008T5 (xx)
HR (1) HRP20130748T4 (xx)
MA (1) MA29353B1 (xx)
ME (1) ME01713B (xx)
MX (1) MX2007012162A (xx)
NO (1) NO343603B1 (xx)
NZ (1) NZ561940A (xx)
PL (1) PL1863487T5 (xx)
PT (1) PT1863487E (xx)
RS (1) RS52911B2 (xx)
SG (1) SG147415A1 (xx)
SI (1) SI1863487T2 (xx)
TN (1) TNSN07365A1 (xx)
UA (1) UA94902C2 (xx)
WO (1) WO2006103546A2 (xx)
ZA (1) ZA200708086B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
SG173312A1 (en) 2006-06-23 2011-08-29 Abbott Lab Cyclopropyl amine derivatives as histamin h3 receptor modulators
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
BRPI0713836A2 (pt) 2006-07-25 2013-05-28 Cephalon Inc composto, composiÇço farmacÊutica e mÉtodo para tratar distérbio
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
EP2250176B1 (en) 2008-01-30 2012-08-01 Cephalon, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
FR2932479A1 (fr) * 2008-06-13 2009-12-18 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
US9181275B2 (en) 2011-08-11 2015-11-10 Abbvie Inc. Mercaptoamidine derivatives and methods of use
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
SG11201502210VA (en) * 2012-10-05 2015-04-29 Vtvx Holdings I Llc Treatment of mild and moderate alzheimer's disease
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US20200281522A1 (en) 2019-03-06 2020-09-10 Medtronic Xomed, LLC System and method for improved obstructive sleep apnea diagnostic for implantable devices
EP4248969A1 (en) 2022-03-23 2023-09-27 Bioprojet Use of pitolisant for treating severe fatigue

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815945A (ja) * 1981-07-21 1983-01-29 Teikoku Hormone Mfg Co Ltd 新規なフエノキシアルキルアミン誘導体
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
ES2108107T3 (es) 1991-02-27 1997-12-16 Seed Capital Investments Derivados de imidazol que tienen actividad antagonista en el receptor h3 de histamina.
IL104125A (en) 1991-12-18 2000-08-31 Schering Corp Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring and pharmaceutical compositions comprising them
ES2089782T3 (es) 1991-12-18 1996-10-01 Schering Corp Imidazolalquilo sustituido con un anillo heterociclico que contiene nitrogeno de seis elementos.
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5380858A (en) 1992-04-01 1995-01-10 The University Of Toledo Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
US5639775A (en) 1992-04-01 1997-06-17 The University Of Toledo 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof
US5486526A (en) * 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
EP0680960A4 (en) 1993-01-25 1997-05-14 Green Cross Corp IMIDAZOLE CONNECTION.
JP3522790B2 (ja) 1993-06-08 2004-04-26 花王株式会社 Ｈ３−レセプター刺激薬
AU7823894A (en) 1993-08-27 1995-03-21 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
AU693142B2 (en) 1993-11-15 1998-06-25 Schering Corporation Phenyl-alkyl imidazoles as H3-receptor antagonists
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
US5652258A (en) 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
CN1192144A (zh) 1995-05-30 1998-09-02 格里亚特克公司 1h－4(5)－取代的咪唑衍生物
CA2222652A1 (en) 1995-06-07 1996-12-19 Gliatech, Inc. 1h-4(5)-substituted imidazole derivatives
AU709611B2 (en) 1996-02-09 1999-09-02 James Black Foundation Limited Histamine h3 receptor ligands
JP3925579B2 (ja) * 1998-02-03 2007-06-06 日本精工株式会社 潤滑剤供給体、並びに前記潤滑剤供給体を備える転がり軸受、リニアガイド装置及びボールねじ装置
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
PT1186594E (pt) * 1999-06-11 2009-10-13 Toyama Chemical Co Ltd Derivados de n-alcoxialquil-n,n-dialquilamina ou os seus sais e medicamentos que os contêm para doenças de degeneração dos nervos
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
KR100819381B1 (ko) * 2000-08-08 2008-04-04 오르토-맥네일 파마슈티칼, 인코퍼레이티드 비-이미다졸 아릴옥시알킬아민
EP1313470A4 (en) * 2000-08-17 2005-02-16 Gliatech Inc NEW ALICYCLIC IMIDAZOLE AS H 3 ACTIVE SUBSTANCES
EP1320364A1 (en) * 2000-08-21 2003-06-25 Gliatech, Inc. The use of histamine h3-receptor inverse agonists for the control of appetite and treatment of obesity
DE60224509T2 (de) * 2001-03-29 2009-03-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazolderivate verwendbar als histamin h3 rezeptorliganden
WO2003044059A1 (en) * 2001-11-15 2003-05-30 Ortho-Mcneil Pharmaceutical, Inc. Agonists of recombinant human histamine h3 receptor
NZ533990A (en) * 2001-12-10 2006-04-28 Ortho Mcneil Pharm Inc Phenylalkyne compounds useful for the treatment of disorders and conditions modulated by a histamine receptor
EP1556046A1 (en) * 2002-10-23 2005-07-27 Janssen Pharmaceutica N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
JP4735261B2 (ja) * 2003-06-27 2011-07-27 Ｍｓｄ株式会社 ヘテロアリールオキシ含窒素飽和ヘテロ環誘導体
FR2856596B1 (fr) * 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
SE0302116D0 (sv) * 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
JP4765627B2 (ja) * 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体

Also Published As

Publication number Publication date
EP1863487B2 (en) 2019-07-17
JP2014062126A (ja) 2014-04-10
SI1863487T1 (sl) 2013-09-30
MA29353B1 (fr) 2008-03-03
AU2006228413A1 (en) 2006-10-05
HRP20130748T4 (hr) 2019-11-15
TNSN07365A1 (fr) 2008-12-31
ES2426008T3 (es) 2013-10-18
HRP20130748T1 (xx) 2013-10-11
AU2006228413B2 (en) 2011-09-15
BRPI0612216B1 (pt) 2022-04-19
JP2008534572A (ja) 2008-08-28
EA200702135A1 (ru) 2008-04-28
CY1114636T1 (el) 2016-10-05
DK1863487T3 (da) 2013-08-12
MX2007012162A (es) 2007-11-22
CN101171009A (zh) 2008-04-30
EP1707203A1 (en) 2006-10-04
KR101308527B1 (ko) 2013-09-17
JP5546761B2 (ja) 2014-07-09
US20090318433A1 (en) 2009-12-24
CN101171009B (zh) 2012-11-07
JP5955872B2 (ja) 2016-07-20
PL1863487T3 (pl) 2014-10-31
SG147415A1 (en) 2008-11-28
CA2603656A1 (en) 2006-10-05
PT1863487E (pt) 2013-08-29
ES2426008T5 (es) 2020-03-20
NZ561940A (en) 2010-06-25
NO20075086L (no) 2007-12-27
BRPI0612216A2 (pt) 2010-10-26
NO343603B1 (no) 2019-04-08
DK1863487T4 (da) 2019-10-14
ME01713B (me) 2014-09-20
UA94902C2 (ru) 2011-06-25
WO2006103546A3 (en) 2007-03-01
WO2006103546A2 (en) 2006-10-05
SI1863487T2 (sl) 2019-11-29
PL1863487T5 (pl) 2021-08-09
US8486947B2 (en) 2013-07-16
RS52911B (en) 2014-02-28
KR20080002904A (ko) 2008-01-04
EP1863487A2 (en) 2007-12-12
CA2603656C (en) 2015-06-16
EA016007B1 (ru) 2012-01-30
RS52911B2 (sr) 2019-11-29
AU2006228413C1 (en) 2012-02-02
JP2016106142A (ja) 2016-06-16
EP1863487B1 (en) 2013-05-29

Similar Documents

Publication Publication Date Title
ZA200708086B (en) Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands
IL249715A0 (en) A method for the treatment of glycogenosis in inventions using the history of 1-deoxybojiramycin
PT1613296E (pt) Métodos para o tratamento da doença de parkinson
IL192241A (en) A process for making 4 - (benzimidazolylmethylamino) - benzamides and their salts
EP1896457A4 (en) NEW 2-AZETIDINONE DERIVATIVES SUITABLE FOR THE TREATMENT OF HYPERLIPIDOMIC SUFFERINGS
EP1925617A4 (en) Heterocyclic compound, method of preparation and use
IL178815A0 (en) The treatment of respiratory disease
EP1945628A4 (en) NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY, AND THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER DISEASE
EP1738735A4 (en) MEDICAL BED
EP1853186A4 (en) CATHETER FOR THERMAL TREATMENT
IL180680A0 (en) Piperazine derivatives useful for the treatment of gastrointestinal disorders
PL378587A1 (pl) Sposób wytwarzania (S)-(-)-2-amino-6-n-propyloamino-4,5,6,7-tetrahydrobenzotiazolu i/lub jego soli
IL184059A0 (en) Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexylphenyl]piperazine
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
DE602006001590D1 (de) 7-(2-(4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)ethyl)isochinolin-besylatsalz, dessen herstellung und dessen therapeutische verwendung
GB0410399D0 (en) The treatment of respiratory disease
EP1867623A4 (en) Terephthalic derivatives, tetrahalothiophenyl derivatives and processes for their preparation
EP1753446A4 (en) ALPHA-1 GLYCOPROTEIN ACID FOR THE TREATMENT OF DIABETES
IL199902A0 (en) Orotate antimetabolite derivatives, methods of producing the same and uses thereof
IL184849A0 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
PL1732558T3 (pl) Pochodne 1-[2H-1-benzopiran-2-on-8-ylo]-piperazyny do leczenia bólu
HK1106223A1 (en) 6-substituted pyridoindolone derivatives production and therapeutic use ; thereof 6-
TWI340643B (en) 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of movement disorders
EP1863510A4 (en) METHOD FOR TREATING PARKINSON DISEASE
SG126063A1 (en) Methods for the treatment of insulin resistance and disease states characterized by insulin resistance